These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 8955652)

  • 1. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
    Rowinsky EK; Kaufmann SH; Baker SD; Grochow LB; Chen TL; Peereboom D; Bowling MK; Sartorius SE; Ettinger DS; Forastiere AA; Donehower RC
    J Clin Oncol; 1996 Dec; 14(12):3074-84. PubMed ID: 8955652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
    Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
    J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
    O'Reilly S; Fleming GF; Barker SD; Walczak JR; Bookman MA; McGuire WP; Schilder RJ; Alvarez RD; Armstrong DK; Horowitz IR; Ozols RF; Rowinsky EK
    J Clin Oncol; 1997 Jan; 15(1):177-86. PubMed ID: 8996140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
    Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.
    Ricart AD; Hammond LA; Kuhn JG; Takimoto CH; Goetz A; Forouzesh B; Forero L; Ochoa-Bayona JL; Berg K; Tolcher AW; Rowinsky EK
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8728-36. PubMed ID: 16361560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
    Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.
    Frasci G; Panza N; Comella P; Cartení G; Guida T; Nicolella GP; Natale M; Lombardi R; Apicella A; Pacilio C; Gravina A; Lapenta L; Comella G
    Ann Oncol; 1999 Mar; 10(3):355-8. PubMed ID: 10355583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer.
    Murren JR; Anderson S; Fedele J; Pizzorno G; Belliveau D; Zelterman D; Burtness BA; Tocino I; Flynn SD; Beidler D; Cheng YC
    J Clin Oncol; 1997 Jan; 15(1):148-57. PubMed ID: 8996136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma.
    Raymond E; Burris HA; Rowinsky EK; Eckardt JR; Rodriguez G; Smith L; Weiss G; Von Hoff DD
    Ann Oncol; 1997 Oct; 8(10):1003-8. PubMed ID: 9402174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
    Ma J; Maliepaard M; Nooter K; Boersma AW; Verweij J; Stoter G; Schellens JH
    Cancer Chemother Pharmacol; 1998; 41(4):307-16. PubMed ID: 9488600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of docetaxel and topotecan in patients with solid tumors.
    Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
    Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
    Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
    J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
    Rowinsky EK; Grochow LB; Hendricks CB; Ettinger DS; Forastiere AA; Hurowitz LA; McGuire WP; Sartorius SE; Lubejko BG; Kaufmann SH
    J Clin Oncol; 1992 Apr; 10(4):647-56. PubMed ID: 1312588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
    Rowinsky EK; Adjei A; Donehower RC; Gore SD; Jones RJ; Burke PJ; Cheng YC; Grochow LB; Kaufmann SH
    J Clin Oncol; 1994 Oct; 12(10):2193-203. PubMed ID: 7931489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.
    de Jonge MJ; Loos WJ; Gelderblom H; Planting AS; van der Burg ME; Sparreboom A; Brouwer E; van Beurden V; Mantel MA; Doyle E; Hearn S; Ross G; Verweij J
    J Clin Oncol; 2000 May; 18(10):2104-15. PubMed ID: 10811676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
    Tolcher AW; O'Shaughnessy JA; Weiss RB; Zujewski J; Myhand RC; Schneider E; Hakim F; Gress R; Goldspiel B; Noone MH; Brewster LR; Gossard MR; Cowan KH
    Clin Cancer Res; 1997 May; 3(5):755-60. PubMed ID: 9815746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
    Herben VM; Panday VR; Richel DJ; Schellens JH; van der Vange N; Rosing H; Beusenberg FD; Hearn S; Doyle E; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Mar; 17(3):747-55. PubMed ID: 10071262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.
    Rowinsky EK; Baker SD; Burks K; O'Reilly S; Donehower RC; Grochow LB
    Ann Oncol; 1998 Feb; 9(2):173-80. PubMed ID: 9553662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.